Introduction Immune checkpoint inhibitors (ICIs) are now approved for at least 17 different cancer types, and have resulted in increased patient survival.1 As of March 2020, an estimated 38.5% of patients are eligible to receive ICIs and more than 230,000 patients had been treated at that time.2 The recent Food and Drug Administration (FDA) approval of relatlimab brings to the total of FDA-approved agents to 10, and a number of eligible patients for ICI therapy continues to rise.3 4 With improved survival due to durable responses, and the use of therapy in earlier stages of disease, the importance of studying long-term outcomes has increased
The muscle and bone risks are more serious for seniors
Moreover, vitamin D upregulates TRAF3 expression to inhibit the noncanonical NF-B2 pathway, alleviating the inflammatory state in end-stage renal disease (ESRD) patients and animal models (22)
While commercially available options like Wegovy and Ozempic are effective, compounded semaglutide offers the flexibility to adjust dosages and formulations to meet individual requirements
Many patients experience weight reduction (typically 3-6 kg at diabetes doses), though it's important to note that Ozempic is not licensed in the UK for weight management
